Differential effects of therapeutic complement inhibitors on serum bactericidal activity against non-groupable meningococcal isolates recovered from patients treated with eculizumab

Haematologica. 2019 Aug;104(8):e340-e344. doi: 10.3324/haematol.2018.209692. Epub 2019 Jan 31.

Authors

Dan M Granoff¹, Howard Kim², Nadav Topaz³, Jessica MacNeil³, Xin Wang³, Lucy A McNamara³

Affiliations

¹ Center for Immunobiology and Vaccine Development, UCSF Benioff Children's Hospital Oakland, Oakland, CA dgranoff@chori.org.
² Center for Immunobiology and Vaccine Development, UCSF Benioff Children's Hospital Oakland, Oakland, CA.
³ Meningitis and Vaccine Preventable Diseases Branch, Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Anti-Bacterial Agents / pharmacokinetics*
Anti-Bacterial Agents / therapeutic use
Antibodies, Monoclonal, Humanized / adverse effects*
Antibodies, Monoclonal, Humanized / therapeutic use
Complement Inactivating Agents / adverse effects*
Complement Inactivating Agents / therapeutic use
Disease Susceptibility
Drug Antagonism
Humans
Meningococcal Infections / diagnosis*
Meningococcal Infections / drug therapy
Meningococcal Infections / etiology*
Meningococcal Infections / prevention & control
Meningococcal Vaccines / administration & dosage
Meningococcal Vaccines / immunology
Neisseria meningitidis / classification
Neisseria meningitidis / isolation & purification*

Substances

Anti-Bacterial Agents
Antibodies, Monoclonal, Humanized
Complement Inactivating Agents
Meningococcal Vaccines
eculizumab

Grants and funding